【摘要】 目的：观察白蛋白结合型紫杉醇和溶剂型紫杉醇治疗晚期乳腺癌的效果和神经毒性。方法：选择2019年10月—2021年3月于上饶市人民医院就诊的50例晚期乳腺癌患者作为研究对象，进行随机分组，对照组25例，观察组25例，均治疗三个周期，比较两组患者的治疗效果和毒副反应情况。结果：对比两组患者疗效情况，治疗组和对照组的客观缓解率（ORR）分别为52.00%、24.00%，差异有统计学意义（χ~2=4.1596,P<0.05）。两组患者均出现毒副反应，在白细胞减少、恶心呕吐、过敏、脱发、反酸、失眠等方面毒副反应类似，差异无统计学意义（χ~2=0.738 9、0.116 6、0、0.724 6、0.189 4、0.986 8,P>0.05）。但在神经毒性方面两组患者比较，差异有统计学意义（χ~2=6.650 2,P<0.05），白蛋白紫杉醇明显更高，达60.00%。但是主要是1～2级神经毒性居多达52.00%，而溶剂型紫杉醇只有24.00%。采取适当的处理后，神经毒性可控，不影响继续治疗。结论：白蛋白结合型紫杉醇治疗晚期乳腺癌的临床疗效较为良好，并且其不良反应相对可控，是化疗排兵布阵中一个重要的选择。更多还原

【Abstract】 Objective:To observe the efficacy and neurotoxicity of albumin-bound paclitaxel and solvent-based paclitaxel in the treatment of advanced breast cancer.Methods:50 patients with advanced breast cancer attending the hospital from October2019 to March 2021 were randomly grouped, 25 in the control group and 25 in the observation group. Both groups were treated for three cycles, and the treatment effects and toxic side effects of the two groups were compared.Results:The objective remission rates(ORR) in the treatment and control groups were 52.00% and 24.00%, respectively, with statistically significant differences(χ~2=4.1596, P<0.05). Patients in both groups experienced toxic side effects, with no statistically significant differences when compared in leukopenia, nausea and vomiting, allergy, alopecia, acid reflux, and insomnia(χ~2=0.738 9, 0.116 6, 0.000 0, 0.724 6, 0.189 4,0.986 8, P>0.05). The difference in neurotoxicity between the two groups was statistically significant(χ~2=6.650 2, P<0.05), with albumin paclitaxel significantly higher at 60.00%. Primarily, grade 1 to 2 neurotoxicity was predominant at 52.00%, while solvent-based paclitaxel was only 24.00%. With appropriate treatment, the neurotoxicity was manageable and did not affect the continuation of treatment.Conclusion:The clinical efficacy of albumin-bound paclitaxel in the treatment of advanced breast cancer is relatively good and its adverse effects are relatively manageable, making it an important option in the chemotherapy line-up.更多还原